Asset Management One Co. Ltd. Increases Stake in Insulet Co. (NASDAQ:PODD)

Asset Management One Co. Ltd. lifted its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 33.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 36,677 shares of the medical instruments supplier's stock after acquiring an additional 9,240 shares during the period. Asset Management One Co. Ltd. owned 0.05% of Insulet worth $8,048,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Parkside Financial Bank & Trust increased its holdings in shares of Insulet by 251.0% during the third quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier's stock valued at $27,000 after acquiring an additional 123 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Insulet by 104.5% in the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 92 shares during the last quarter. Wolff Wiese Magana LLC lifted its position in Insulet by 2,680.0% in the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier's stock valued at $30,000 after acquiring an additional 134 shares in the last quarter. BluePath Capital Management LLC acquired a new position in Insulet during the 3rd quarter valued at about $31,000. Finally, First Manhattan Co. bought a new stake in Insulet during the 4th quarter worth approximately $35,000.

Wall Street Analysts Forecast Growth

PODD has been the topic of several analyst reports. JPMorgan Chase & Co. lifted their target price on Insulet from $190.00 to $225.00 and gave the company an "overweight" rating in a research report on Friday, February 23rd. Piper Sandler reduced their target price on shares of Insulet from $250.00 to $230.00 and set an "overweight" rating for the company in a research note on Friday, February 23rd. Stifel Nicolaus raised their price target on shares of Insulet from $163.00 to $208.00 and gave the company a "hold" rating in a research report on Monday, February 5th. Barclays cut their price target on shares of Insulet from $214.00 to $213.00 and set an "equal weight" rating on the stock in a report on Monday, February 26th. Finally, Robert W. Baird upgraded shares of Insulet from a "neutral" rating to an "outperform" rating and increased their price objective for the company from $180.00 to $238.00 in a research note on Thursday, December 21st. Four research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $250.33.

Insider Activity at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of Insulet stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the transaction, the director now directly owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.80% of the stock is currently owned by corporate insiders.

Insulet Stock Performance

NASDAQ:PODD traded up $7.97 during trading hours on Tuesday, reaching $178.01. The stock had a trading volume of 939,708 shares, compared to its average volume of 893,964. The stock has a market cap of $12.45 billion, a P/E ratio of 61.17, a price-to-earnings-growth ratio of 2.97 and a beta of 0.98. The stock has a 50 day simple moving average of $177.68 and a 200 day simple moving average of $178.43. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. Insulet Co. has a 12-month low of $125.82 and a 12-month high of $335.91.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.73. The business had revenue of $509.80 million for the quarter, compared to analysts' expectations of $461.26 million. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The firm's quarterly revenue was up 37.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.55 EPS. On average, research analysts forecast that Insulet Co. will post 3.08 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.